JP2020501577A5 - - Google Patents

Download PDF

Info

Publication number
JP2020501577A5
JP2020501577A5 JP2019533340A JP2019533340A JP2020501577A5 JP 2020501577 A5 JP2020501577 A5 JP 2020501577A5 JP 2019533340 A JP2019533340 A JP 2019533340A JP 2019533340 A JP2019533340 A JP 2019533340A JP 2020501577 A5 JP2020501577 A5 JP 2020501577A5
Authority
JP
Japan
Prior art keywords
antibody
solution
affinity ligand
light chain
stationary phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533340A
Other languages
English (en)
Japanese (ja)
Other versions
JP6850351B2 (ja
JP2020501577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/083429 external-priority patent/WO2018114877A1/en
Publication of JP2020501577A publication Critical patent/JP2020501577A/ja
Publication of JP2020501577A5 publication Critical patent/JP2020501577A5/ja
Application granted granted Critical
Publication of JP6850351B2 publication Critical patent/JP6850351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533340A 2016-12-21 2017-12-19 抗体のインビトロ糖鎖工学 Active JP6850351B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16205587.5 2016-12-21
EP16205587 2016-12-21
EP17157002 2017-02-20
EP17157002.1 2017-02-20
PCT/EP2017/083429 WO2018114877A1 (en) 2016-12-21 2017-12-19 In vitro glycoengineering of antibodies

Publications (3)

Publication Number Publication Date
JP2020501577A JP2020501577A (ja) 2020-01-23
JP2020501577A5 true JP2020501577A5 (enExample) 2021-01-07
JP6850351B2 JP6850351B2 (ja) 2021-03-31

Family

ID=60997429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533340A Active JP6850351B2 (ja) 2016-12-21 2017-12-19 抗体のインビトロ糖鎖工学

Country Status (11)

Country Link
US (2) US20200165320A1 (enExample)
EP (1) EP3559248B2 (enExample)
JP (1) JP6850351B2 (enExample)
KR (1) KR102317884B1 (enExample)
CN (2) CN110088291A (enExample)
AU (1) AU2017384276B9 (enExample)
CA (1) CA3044920C (enExample)
IL (1) IL267351A (enExample)
MX (1) MX2019006266A (enExample)
TW (1) TWI780097B (enExample)
WO (1) WO2018114877A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887794A (zh) * 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
US20230272105A1 (en) 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025049881A1 (en) * 2023-09-01 2025-03-06 Catalent Pharma Solutions, Llc Dnase co-expression in host cells

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0576592B1 (en) 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US20070266448A1 (en) 2006-05-11 2007-11-15 Alexander Lifke Method for the production of antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2008291358A1 (en) * 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
SG177764A1 (en) * 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2012037407A1 (en) 2010-09-17 2012-03-22 Prozyme, Inc. Isolation and deglycosylation of glycoproteins
PT2768857T (pt) * 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
IN2014DN06806A (enExample) * 2012-02-10 2015-05-22 Univ Maryland
EP3108004B1 (en) * 2014-02-18 2019-02-20 The University of Manitoba Methods to produce single glycoform antibodies
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작

Similar Documents

Publication Publication Date Title
JP2020501577A5 (enExample)
Hayes et al. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions
Mahan et al. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis
Huhn et al. IgG glycosylation analysis
TWI670279B (zh) 抗體純化及純度監測
JP6419844B2 (ja) Ｃｙｓ連結された抗体−薬物コンジュゲートの精製方法
CN106604930B (zh) 去糖基化试剂和方法
CN102308216B (zh) 免疫球蛋白糖基化模式分析
US20170205423A1 (en) Method of Mapping Glycans of Glycoproteins in Serum Samples
US12157756B2 (en) Detection and quantification of glycosylated peptides
EP3196646B1 (en) Methods of mapping protein variants
RU2018121653A (ru) Улучшенное разделение белков при ионообменной хроматографии
Tayi et al. Isolation and quantification of N-glycans from immunoglobulin G antibodies for quantitative glycosylation analysis
KR20210148349A (ko) 크로마토그래피 수지의 재생 방법
Bodnar et al. An integrated approach to analyze EG2-hFc monoclonal antibody N-glycosylation by MALDI-MS
Capela et al. Monoclonal Antibodies Addressing the Challenges on the Manufacturing Processing of an Advanced Class of Therapeutic Agents
WO2012015028A1 (ja) 抗体の糖鎖を調製する方法
JP7673905B2 (ja) 左右非対称の糖鎖を有する抗体を均一に含む抗体集団、及びその製造方法
JP2025510508A (ja) 宿主細胞タンパク質を特徴付けるためのサイズ排除クロマトグラフィ
Bresolin et al. Purification of anti-interleukin-6 monoclonal antibody using precipitation and immobilized metal-ion affinity chromatography
WO2018186063A1 (ja) 糖鎖を調製する方法
ZHENG et al. 1 CHARACTERIZATION OF MONOCLONAL ANTIBODY HETEROGENEITY BY HPLC ANALYSIS
Plavša et al. N-Glycans of Both Fc and Fab Regions of IgG are Changed in Children with Type 1 Diabetes
EP3774878A1 (en) Separation method
HK40044470B (en) Detection and quantification of glycosylated peptides